LAB vs. PACB, ADPT, OLK, TXG, CTKB, QTRX, EYPT, NAUT, HBIO, and SEER
Should you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include Pacific Biosciences of California (PACB), Adaptive Biotechnologies (ADPT), Olink Holding AB (publ) (OLK), 10x Genomics (TXG), Cytek Biosciences (CTKB), Quanterix (QTRX), EyePoint Pharmaceuticals (EYPT), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), and Seer (SEER).
Standard BioTools (NASDAQ:LAB) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.
Pacific Biosciences of California received 442 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 67.32% of users gave Pacific Biosciences of California an outperform vote.
Standard BioTools has a net margin of -70.98% compared to Pacific Biosciences of California's net margin of -148.13%. Pacific Biosciences of California's return on equity of -40.26% beat Standard BioTools' return on equity.
Standard BioTools currently has a consensus target price of $3.58, suggesting a potential upside of 44.49%. Pacific Biosciences of California has a consensus target price of $6.59, suggesting a potential upside of 268.21%. Given Pacific Biosciences of California's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than Standard BioTools.
In the previous week, Pacific Biosciences of California had 3 more articles in the media than Standard BioTools. MarketBeat recorded 5 mentions for Pacific Biosciences of California and 2 mentions for Standard BioTools. Pacific Biosciences of California's average media sentiment score of 0.96 beat Standard BioTools' score of 0.93 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.
53.7% of Standard BioTools shares are held by institutional investors. 53.1% of Standard BioTools shares are held by company insiders. Comparatively, 1.9% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Standard BioTools has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500.
Standard BioTools has higher earnings, but lower revenue than Pacific Biosciences of California. Standard BioTools is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.
Summary
Standard BioTools and Pacific Biosciences of California tied by winning 9 of the 18 factors compared between the two stocks.
Get Standard BioTools News Delivered to You Automatically
Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Standard BioTools Competitors List
Related Companies and Tools
